Omega One

Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines. Utilizing its proprietary OMEGA platform, the company designs Omega Epigenomic Controllers (OECs) to precisely tune the expression of genes by targeting their epigenetic regulatory elements. This approach allows for the transient and reversible control of gene expression without altering the underlying DNA sequence. The company's lead candidate, OTX-2002, is currently being evaluated in a Phase 1 clinical trial for the treatment of hepatocellular carcinoma and other solid tumors. Omega's pipeline also includes programs targeting inflammatory diseases, fibrotic conditions, and metabolic disorders.